JAZZ Stock Overview
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally.
Jazz Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$136.76|
|52 Week High||US$189.00|
|52 Week Low||US$117.64|
|1 Month Change||6.69%|
|3 Month Change||-4.15%|
|1 Year Change||-18.91%|
|3 Year Change||7.74%|
|5 Year Change||14.46%|
|Change since IPO||671.35%|
Recent News & Updates
|JAZZ||US Pharmaceuticals||US Market|
Return vs Industry: JAZZ underperformed the US Pharmaceuticals industry which returned 5.3% over the past year.
Return vs Market: JAZZ underperformed the US Market which returned 4.2% over the past year.
|JAZZ Average Weekly Movement||4.7%|
|Pharmaceuticals Industry Average Movement||10.6%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: JAZZ is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: JAZZ's weekly volatility (5%) has been stable over the past year.
About the Company
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer.
Jazz Pharmaceuticals Fundamentals Summary
|JAZZ fundamental statistics|
Is JAZZ overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|JAZZ income statement (TTM)|
|Cost of Revenue||US$206.13m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.62|
|Net Profit Margin||-5.62%|
How did JAZZ perform over the long term?See historical performance and comparison
Is Jazz Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: JAZZ ($136.76) is trading below our estimate of fair value ($565.45)
Significantly Below Fair Value: JAZZ is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: JAZZ is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: JAZZ is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate JAZZ's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: JAZZ's PB Ratio (2.1x) is in line with the US Pharmaceuticals industry average.
How is Jazz Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JAZZ is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: JAZZ is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: JAZZ's is expected to become profitable in the next 3 years.
Revenue vs Market: JAZZ's revenue (8.3% per year) is forecast to grow slower than the US market (9.1% per year).
High Growth Revenue: JAZZ's revenue (8.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: JAZZ's Return on Equity is forecast to be high in 3 years time (22.2%)
How has Jazz Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: JAZZ is currently unprofitable.
Growing Profit Margin: JAZZ is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: JAZZ is unprofitable, and losses have increased over the past 5 years at a rate of 15.7% per year.
Accelerating Growth: Unable to compare JAZZ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JAZZ is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: JAZZ has a negative Return on Equity (-4.09%), as it is currently unprofitable.
How is Jazz Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: JAZZ's short term assets ($2.6B) exceed its short term liabilities ($735.1M).
Long Term Liabilities: JAZZ's short term assets ($2.6B) do not cover its long term liabilities ($7.8B).
Debt to Equity History and Analysis
Debt Level: JAZZ's net debt to equity ratio (142.9%) is considered high.
Reducing Debt: JAZZ's debt to equity ratio has increased from 127% to 159.9% over the past 5 years.
Debt Coverage: JAZZ's debt is not well covered by operating cash flow (12.5%).
Interest Coverage: JAZZ's interest payments on its debt are well covered by EBIT (3.2x coverage).
What is Jazz Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate JAZZ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate JAZZ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if JAZZ's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if JAZZ's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of JAZZ's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bruce Cozadd (57 yo)
Mr. Bruce C. Cozadd serves as Member of Board of Advisors at Cellares Corp. He co-founded Jazz Pharmaceuticals Public Limited Company in 2003 and has been Chairman and Chief Executive Officer since April 2...
CEO Compensation Analysis
Compensation vs Market: Bruce's total compensation ($USD12.57M) is above average for companies of similar size in the US market ($USD6.49M).
Compensation vs Earnings: Bruce's compensation has been consistent with company performance over the past year.
Experienced Management: JAZZ's management team is considered experienced (2.4 years average tenure).
Experienced Board: JAZZ's board of directors are considered experienced (9.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: JAZZ insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.3%.
Jazz Pharmaceuticals plc's employee growth, exchange listings and data sources
- Name: Jazz Pharmaceuticals plc
- Ticker: JAZZ
- Exchange: NasdaqGS
- Founded: 2003
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$8.407b
- Shares outstanding: 61.47m
- Website: https://www.jazzpharma.com
Number of Employees
- Jazz Pharmaceuticals plc
- Waterloo Exchange
- Fifth Floor
- Co. Dublin
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/23 23:14|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.